On August 3, 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "We remain focused on long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline through targeted corporate development and internal research and development. The combination of commercial execution, portfolio expansion and our strong financial foundation positions Jazz to deliver meaningful innovation for patients and substantial value for shareholders."

Recent Key Highlights

•Highest ever total quarterly revenues of $1.2 billion with 16% year-over-year (YoY) growth.
•Generated GAAP / non-GAAP1 adjusted earnings per share (EPS) of $2.78 / $5.71 with $824 million in cash from operations in the first half of 2026.
•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA).
•Results from Phase 3 HERIZON-GEA-01 published in The New England Journal of Medicine; additional subgroup analyses presented in an oral presentation at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting showing improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients.
•FDA granted Breakthrough Therapy designation (BTD) for zanidatamab in adults with previously treated locally advanced, unresectable, or metastatic HER2-positive colorectal cancer (CRC).
•Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.60 – $4.75 billion, reflecting anticipated double-digit YoY revenue growth from both Xywav and the combined epilepsy and oncology franchises.

Business Updates

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
•Xywav net product sales increased 13% YoY to $471 million in 2Q26.
•Robust new patient growth, with approximately 525 net patient adds in 2Q26. There were approximately 17,125 active patients exiting the quarter, comprised of approximately 11,275 narcolepsy patients and approximately 5,850 idiopathic hypersomnia (IH) patients.
•Continued physician and patient demand for the differentiated benefits of low-sodium Xywav.

Epidiolex/Epidyolex (cannabidiol):
•Epidiolex/Epidyolex net product sales increased 16% YoY to $292 million in 2Q26, driven by continued strong demand.
•Expanded Epidiolex development program to reach more patients with the following clinical trials: Phase 3 trial in developmental and epileptic encephalopathy (DEE), Phase 2/3 trial in juvenile myoclonic epilepsy (JME) and Phase 3b/4 trial in adult Lennox-Gastaut syndrome (LGS).
•Submitted New Drug Application (NDA) for cannabidiol capsule formulation to broaden utilization of cannabidiol in currently approved indications and increase flexibility for patients.

Ziihera (zanidatamab-hrii):
•Ziihera net product sales in biliary tract cancer (BTC) were $15 million in 2Q26.
•Prepared to launch zanidatamab in HER2+ 1L GEA (PDUFA date of August 25, 2026).
•Top-line results from the second interim overall survival (OS) analysis for the HERIZON-GEA-01 trial doublet regimen are expected in 3Q26.

Modeyso (dordaviprone):
•Modeyso net product sales were $48 million in 2Q26 with more than 600 patients having received Modeyso from product launch in August 2025 through the end of the second quarter of 2026.
•Anticipate the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on current pace of event accrual.

Zepzelca (lurbinectedin):
•Zepzelca net product sales increased 42% YoY to $106 million in 2Q26, driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance ES-SCLC setting, partially offset by a decline in second-line use.
•Based on the results from the LAGOON trial of Zepzelca in second-line metastatic SCLC, and in alignment with FDA, in 3Q26, we will submit for FDA’s review and subsequent action a labeling supplement to remove the second-line indication. The first-line maintenance indication will not be affected.

Corporate Development:
•Announced a preclinical research collaboration with AbCellera Biologics Inc. (AbCellera), to develop next-generation T-cell engaging multispecific antibodies for multiple gastrointestinal (GI) cancers and other solid tumors.
•The company continues to actively evaluate additional value-enhancing corporate development.

Financial Highlights
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except per share amounts) 2026 2025 2026 2025
Total revenues $ 1,208.3 $ 1,045.7 $ 2,277.2 $ 1,943.5
GAAP net income (loss) $ 192.8 $ (718.5) $ 485.9 $ (811.0)
Non-GAAP adjusted net income (loss) $ 396.4 $ (504.8) $ 815.9 $ (399.6)
GAAP earnings (loss) per share $ 2.78 $ (11.74) $ 7.17 $ (13.28)
Non-GAAP adjusted earnings (loss) per share $ 5.71 $ (8.25) $ 12.04 $ (6.54)

GAAP and non-GAAP adjusted net income in 2Q26 includes acquired in-process research and development (IPR&D) expense of $77.0 million, relating to upfront payments made in connection with our collaboration and license agreement with AbCellera and asset purchase agreement to acquire remaining rights for JZP898 from Werewolf Therapeutics, Inc. (Werewolf). This impacted our GAAP and non-GAAP adjusted results by $65.4 million (net of tax of $11.6 million) or $0.94 per share.
GAAP and non-GAAP adjusted net loss in 2Q25 includes acquired IPR&D expense of $905.4 million representing the value allocated to Modeyso in the Chimerix Acquisition, which impacted our results by $14.78 per share and $14.75 per share on a GAAP and non-GAAP adjusted basis, respectively.
Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions) 2026 2025 2026 2025
Xywav $ 471.2 $ 415.3 $ 879.4 $ 760.1
Xyrem 30.5 35.4 61.7 72.6
Sleep 501.7 450.7 941.1 832.7
Epidiolex/Epidyolex 292.1 251.7 541.9 469.4
Epilepsy 292.1 251.7 541.9 469.4
Zepzelca 105.8 74.5 206.8 137.5
Rylaze/Enrylaze 99.5 100.7 203.2 194.9
Defitelio/defibrotide 62.0 48.1 109.4 88.8
Modeyso 48.2 0.5 89.6 0.5
Vyxeos 31.4 44.9 58.0 74.4
Ziihera 15.4 6.0 28.7 8.0
Oncology 362.3 274.7 695.7 504.1
Other — 8.5 2.7 18.8
Product sales, net 1,156.1 985.6 2,181.4 1,825.0
High-sodium oxybate AG royalty revenue 42.2 54.1 78.5 103.0
Other royalty and contract revenues 10.0 6.0 17.3 15.5
Total revenues $ 1,208.3 $ 1,045.7 $ 2,277.2 $ 1,943.5

Total revenues increased 16% in 2Q26 YoY primarily due to higher Xywav, Epidiolex/Epidyolex and Zepzelca net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025.

Operating Expenses and Income Tax Expense (Benefit)
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except percentages) 2026 2025 2026 2025
GAAP:
Cost of product sales $ 116.4 $ 116.3 $ 250.5 $ 220.9
Gross margin on total revenues 90.4% 88.9% 89.0% 88.6%
Selling, general and administrative $ 389.2 $ 358.4 $ 741.9 $ 872.4
% of total revenues 32.2% 34.3% 32.6% 44.9%
Research and development $ 207.5 $ 189.9 $ 403.5 $ 370.6
% of total revenues 17.2% 18.2% 17.7% 19.1%
Acquired in-process research and development $ 77.0 $ 905.4 $ 77.0 $ 905.4
Gain on sale of priority review voucher $ — $ — $ (122.8) $ —
Income tax expense (benefit) $ 18.1 $ (17.2) $ 24.2 $ (35.0)
Effective tax rate 8.6% 2.3% 4.7% 4.1%

Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except percentages) 2026 2025 2026 2025
Non-GAAP adjusted:
Cost of product sales $ 95.1 $ 76.3 $ 185.1 $ 146.0
Gross margin on total revenues 92.1% 92.7% 91.9% 92.5%
Selling, general and administrative $ 343.2 $ 310.3 $ 651.7 $ 782.6
% of total revenues 28.4% 29.7% 28.6% 40.3%
Research and development $ 184.9 $ 167.0 $ 357.2 $ 326.7
% of total revenues 15.3% 16.0% 15.7% 16.8%
Acquired in-process research and development $ 77.0 $ 905.4 $ 77.0 $ 905.4
Income tax expense $ 74.4 $ 42.2 $ 115.6 $ 78.7
Effective tax rate 15.8% (9.1)% 12.4% (24.6)%

Changes in operating expenses and income tax expense (benefit) in 2Q26 over the prior year period are primarily due to the following:
•Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher royalty expenses, driven by higher revenues of Modeyso and Zepzelca, offset on a GAAP basis, by lower acquisition accounting inventory fair value step up expense.
•Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher marketing investment and compensation-related expenses in support of our commercial portfolio.
•Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, driven by higher clinical studies costs, primarily related to zanidatamab.
•Acquired IPR&D, on a GAAP and non-GAAP adjusted basis, in 2Q26 comprised the upfront payments to AbCellera and Werewolf.
•Income tax expense, on a GAAP and non-GAAP adjusted basis, in 2Q26 reflects changes in the geographic mix of income and expenses compared to 2Q25.

(Press release, Jazz Pharmaceuticals, AUG 3, 2026, View Source [SID1234669609])

On August 3, 2026 Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that it has raised $31 million in an oversubscribed Series B-3 financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing brings Inocras’s total funding to approximately $100 million and supports the company’s growth. Inocras plans to expand its whole-genome sequencing and proprietary bioinformatics platform in the United States, building on demonstrated clinical deployment across Asia. As whole-genome sequencing moves toward broader adoption in oncology, Inocras is positioned to build on years of experience translating complex whole-genome data into curated, clinically actionable insights.

The round included participation from new and existing financial investors as well as strategic investors NDS Corporation and Aimed Bio Inc. New investors included IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities. Existing investors DSC Investment, Dunamu & Partners and InterVest also participated.

Inocras has established a record of real-world clinical adoption across Asia, with its whole-genome sequencing solutions currently used by more than 100 cancer institutions and in thousands of patient cases. The company has also established a significant commercial presence in Hong Kong and is supporting approximately thirty hospitals in South Korea.

Through its proprietary bioinformatics and automated interpretation capabilities, Inocras supports precision oncology applications spanning comprehensive tumor profiling with CancerVision and molecular residual disease detection with MRDVision.Across both solutions, the company analyzes genomic alterations and complex biomarkers across the cancer genome and translates those findings into clinically relevant insights. Inocras will use the proceeds to build on this momentum by expanding its U.S. commercial and operational infrastructure.

"We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases," said Jehee Suh, CEO of Inocras. "Our next objective is to bring that clinical experience to the United States and help make whole-genome analysis a standard part of cancer care. This financing gives us the resources to expand our clinical presence, support adoption within hospitals, and build the evidence and infrastructure required to achieve that goal."

The financing follows continued clinical and scientific validation of Inocras’s whole-genome approach. Through its collaboration with researchers at the Broad Institute, Inocras recently analyzed whole-genome data from The Cancer Genome Atlas across thousands of cancer cases, demonstrating the utility of standardized whole-genome analysis at scale and informing broader use of comprehensive genomic information in oncology.

(Press release, Inocras, AUG 3, 2026, View Source [SID1234669625])

On August 3, 2026 Keros therapeutics presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Keros Therapeutics, AUG 3, 2026, View Source [SID1234669610])

On August 3, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs). NECs are aggressive malignancies that frequently express DLL3. There are no available targeted therapies and no approved standard of care for NECs in previously treated patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Zoci has now received important regulatory designations around the world, signifying its potential to become an important new therapeutic option for patients with multiple types of cancer with DLL3 expressions." said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Given the need among the NEC patient community, we are focused on efficiently advancing our clinical programs for this investigational DLL3-targeting ADC."

The U.S. FDA previously granted Fast Track designation (FTD) to zoci for extrapulmonary NECs (epNECs), as well as FTD and ODD to zoci for small cell lung cancer (SCLC), the most significant pulmonary NEC and one of the most aggressive and lethal solid tumors.1,2 The European Medicines Agency (EMA) has also granted ODD to zoci for pulmonary NECs.

Benefits of the ODD include eligibility for certain development incentives, including a waiver of the Prescription Drug User Fee Act registration application fee; tax credits for certain clinical trials; and the potential to receive a seven-year U.S. market exclusivity period granted upon product approval.

About Zocilurtatug Pelitecan (Zoci, ZL-1310)

Zoci targets Delta-like ligand 3 (DLL3), a validated therapeutic target that is overexpressed in many neuroendocrine carcinomas, such as small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinomas (epNEC), and is generally associated with poor clinical outcomes. Zoci is on track to potentially become Zai Lab’s first global oncology launch, with plans for three registration-enabling studies across second- and third-line SCLC, first-line SCLC, and epNECs by the end of 2026. Its potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy, support its potential role as a new standard of care in previously treated extensive-stage SCLC as well as epNEC, and a backbone DLL3-targeting antibody-drug conjugate (ADC) in first-line combination regimens, including those that reduce the burdens of chemotherapy, such as checkpoint inhibitors and T-cell engagers.

(Press release, Zai Laboratory, AUG 3, 2026, View Source [SID1234669626])

On August 3, 2026 Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, reported the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board approval, are consistent with the framework outlined in Lantern’s most recent registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist platform previously launched as withZeta.ai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OMAI will continue to advance the multi-agentic architecture, first proven in oncology and rare cancer research, while expanding its application across broader disease areas. The formation of the entity and the licensing arrangements position OMAI for independent growth, while expanding value creation opportunities and preserving strategic alignment with Lantern Pharma’s clinical programs and shareholders.

AI Centers of Excellence in Dallas, Texas and Bengaluru, India

In the first quarter of 2026, Lantern established and staffed an AI Center of Excellence in Bengaluru, India. This center will serve as a core operational hub accelerating the development, refinement, and scaling of the Open-Medicine platform. The Bengaluru team will bring additional specialized talent to the existing team in Dallas (where Lantern is also headquartered). Both sites will focus on functional enhancements in multi-agent systems, computational biology modeling, knowledge engineering, and large-scale scientific curation — furthering Open-Medicine’s ability to deliver production-grade capabilities to researchers and institutions worldwide.

Market Need and Competitive Landscape

The global market for AI-enabled drug discovery and development tools is projected to exceed $10 billion by 2030, with oncology representing the largest therapeutic segment and compound annual growth rates above 30 percent. The underlying need is structural: traditional drug development remains slow, expensive, and poorly suited to the hundreds of rare and complex diseases that lack commercial scale under conventional models. Knowledge remains fragmented across literature, clinical trial databases, institutional archives, and individual expertise, while experimental iteration continues to consume months or years and hundreds of thousands to millions of dollars per cycle.

At the same time, major general-purpose AI companies — including Anthropic and OpenAI — have publicly signaled or begun developing platforms and tools aimed at scientific discovery and drug development. Their entrance validates the long-term importance of AI co-scientists while also highlighting the differentiation required for durable impact. While general models excel at broad reasoning and language, domain-specific multi-agentic systems grounded in curated ontologies, domain-specific computational tools, and disease-area expertise are required to deliver the precision, auditability, and scientific rigor demanded by drug development.

OMAI is uniquely positioned for differentiated value creation at this intersection. Built from the ground up for oncology and rare disease research and drug-development, the platform combines specialized agent roles, recursive investigation modes, living knowledge graphs, and production tools (including blood-brain barrier prediction, multi-omic analytics via ZetaOmics, and generative chemistry capabilities). Its architecture is designed not merely to retrieve information but to generate, stress-test, and harden insights in a manner that mirrors how expert scientific teams actually work – iteratively, collaboratively and focused on actionable results.

Platform Foundation and Expansion Path

OMAI inherits the full multi-agentic system originally commercialized as withZeta.ai, including:

● Coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers & translational science, clinical oncology, and general research.
● Three research modes (Explorer, Investigator, Reporter) that support rapid exploration through deep multi-source investigation to structured reporting.
● Proprietary rare-cancer knowledge bases and ontologies covering hundreds of disease entities, biomarkers, clinical trials, and literature.
● Expanding computational layers, including ZetaOmics for multi-omic analysis and continued development of parallel swarm intelligence capabilities.

While rare cancers remain a core component, OMAI’s roadmap includes systematic expansion into additional high-need disease areas – especially in collaboration with leading academic and commercial leaders – that experience the same challenges of fragmented knowledge, high failure costs, limited traditional investment and urgency of patient and disease management needs.

"Open-Medicine AI is built to change how medicines are discovered and developed globally, and as a separate company, to pursue dedicated funding and a valuation path distinct from Lantern’s clinical activity and operations." – Panna Sharma, CEO & President of Lantern Pharma

(Press release, Lantern Pharma, AUG 3, 2026, View Source [SID1234669611])